Evidence map›Paper›PMID 41132851›Full record

ArticleActa pharmaceutica Sinica. B2025

Anti-CD24 antibody-nitric oxide donor conjugates bearing a self-bioorthogonal cleavable linker.

Jianbing Wu, Tianyue Cheng, Jiajun Xie, Ziyu Qian, Linhua Huang, Xun Yuan, Libang Zhang, Shan Yang, Yihua Zhang, Tonglin Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jianbing WuState Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 211198, China.
Tianyue ChengAntibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University, Nanjing 211198, China.
Jiajun XieAntibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University, Nanjing 211198, China.
Ziyu QianState Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 211198, China.
Linhua HuangAntibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University, Nanjing 211198, China.
Xun YuanState Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 211198, China.
Libang ZhangState Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 211198, China.
Shan YangSchool of Pharmacy, Key Laboratory of Active Components of Xinjiang Natural Medicine and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Xinjiang Medical University, Urumqi 830054, China.
Yihua ZhangState Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 211198, China.
Tonglin XuNantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong 226006, China.
Juan ZhangAntibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University, Nanjing 211198, China.
Zhangjian HuangState Key Laboratory of Natural Medicines, Center of Drug Discovery, China Pharmaceutical University, Nanjing 211198, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive malignancy predominantly managed

Indexed as

Antibody-nitric oxide donor conjugateBioorthogonal chemistryCD24CisplatinSelf-cleavable linkerSite-specific conjugationTriple-negative breast cancerTumor microenvironment

Identifiers

PMID41132851
PMCPMC12541613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.